IDPH--Positive preliminary results for pivotal trial of ID Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Webhead who wrote (1613)	10/30/1998 4:10:00 AM
From: Maurice Winn	1 Recommendation Read Replies (1) of 1762

Ed, a lymphoma specialist at Scripps Clinic told me in February that the mechanism of action by Rituxan against NHL was unclear. Overall he seemed to have a doubtful view as to its efficacy, saying that he can shrink tumors by half with steroids so wasn't too impressed by some of the response rates of tumors. So the mechanism is not simply a matter of cell identification. Thanks for the half-life explanation for CD20 and that you don't think Rituxan would coat cancer cells and thereby harden them against subsequent Y2B8 treatment. Rituxan doesn't fail in some people. It fails in most people. In as much as not many people are "cured" with no recurrence. Even in tumor suppression the number of complete responses is, to me anyway, not that great. I suppose the failure is because not all cancer cells in a tumor are exposed to the Rituxan, because they are buried inside the tumor with no blood supply. Also, there is, I suppose, a wide variation on the degree of expression of CD20. Meanwhile, the stock jumped $3! Maurice

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next